TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Noble Trims PT on TherapeuticsMD (TXMD) to $17.50 Following Q4 Results; Affirms at 'Buy'
February 26, 2016 12:09 PM ESTNoble Financial affirms TherapeuticsMD (NYSE: TXMD) with a Buy rating, but trimmed its price target from $18 down to $17.50 following the company's Q4 report issued... More
